Table II.
Comparison of PNI, ALI, AGR, CEA, CA19-9 and AFP values before and after immunotherapy in responding and non-responding groups.
| Between time points | Between groups | Interaction | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Variable | Responding group | Non-responding group | P-value |
|
|
|
|||
| F-value | P-value | F-value | P-value | F-value | P-value | ||||
| PNI | |||||||||
| Before immunotherapy | 48.08±5.95 | 43.81±5.93 | <0.001 | 11.879 | 0.001 | 40.874 | <0.001 | 1.933 | 0.166 |
| After immunotherapy | 47.05±5.89 | 41.38±6.61 | <0.001 | ||||||
| P-value | 0.204 | <0.001 | |||||||
| ALI | |||||||||
| Before immunotherapy | 384.08±271.45 | 355.78±300.63 | 0.518 | 0.781 | 0.378 | 0.616 | 0.434 | 0.001 | 0.981 |
| After immunotherapy | 363.03±237.36 | 335.86±287.83 | 0.506 | ||||||
| P-value | 0.574 | 0.468 | |||||||
| AGR | |||||||||
| Before immunotherapy | 1.50±0.22 | 1.31±0.30 | <0.001 | 14.561 | <0.001 | 45.239 | <0.001 | 8.592 | 0.043 |
| After immunotherapy | 1.48±0.29 | 1.18±0.28 | <0.001 | ||||||
| P-value | 0.584 | <0.001 | |||||||
| CEA | |||||||||
| Before immunotherapy | 28.71±51.06 | 69.48±407.03 | 0.412 | 0.942 | 0.333 | 2.771 | 0.098 | 3.941 | 0.049 |
| After immunotherapy | 16.62±24.01 | 104.68±234.65 | 0.002 | ||||||
| P-value | 0.530 | 0.013 | |||||||
| CA19-9 | |||||||||
| Before immunotherapy | 122.66±323.63 | 133.10±282.47 | 0.816 | 0.023 | 0.879 | 3.830 | 0.052 | 4.336 | 0.039 |
| After immunotherapy | 27.03±28.55 | 215.70±680.91 | 0.024 | ||||||
| P-value | 0.168 | 0.104 | |||||||
| AFP | |||||||||
| Before immunotherapy | 41.43±156.59 | 221.78±1066.02 | 0.168 | 1.266 | 0.262 | 1.930 | 0.166 | 1.092 | 0.297 |
| After immunotherapy | 48.98±345.97 | 425.67±2331.69 | 0.187 | ||||||
| P-value | 0.960 | 0.068 | |||||||
Data are expressed as the mean ± standard deviation. PNI, prognostic nutritional index; ALI, advanced lung cancer inflammation index; AGR, albumin-globulin ratio; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen19-9; AFP, α-fetoprotein.